Research Article
High Mobility Group Box 1 (HMGB1) is Associated with Progression and Poor Prognosis in Pancreatic Cancer
Xu Yang Liang1, Qian Qian Li1, Zong Li Zhang2, Chong Qi Jia3, Li Li4, Chun Tao Liu1, Yong Mei Yang5 and Bao Quan Cheng1*1Department of Gastroenterology, Shandong University, China
2Department of Surgery, Shandong University, China
3Department of Epidemiology and Health Statistics, Shandong University, China
4Department of Pathology, Medicine College, Shandong University, China
5Institute of Basic Medical Sciences, Qilu Hospital, Medicine College, Shandong University, China
- *Corresponding Author:
- Bao Quan Cheng, MD, PhD
Department of Gastroenterology
Qilu Hospital, Medicine College
Shandong University, Jinan 250012, China
Tel: +8613853198938
E-mail: drcbq@163.com
Received date: April 30, 2014; Accepted date: June 17, 2014; Published date: June 24, 2014
Citation: Liang XY, Li QQ, Zhang ZL, Jia CQ, Li LI, et al. (2014) High Mobility Group Box 1 (HMGB1) is Associated with Progression and Poor Prognosis in Pancreatic Cancer. J Gastroint Dig Syst 4:190. doi:10.4172/2161-069X.1000190
Copyright: © 2014 Liang XY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Aim: Increased expression of High Mobility Group Protein Box 1(HMGB1) has been reported with several different tumor types, but the role of HMGB1 in pancreatic cancer is not fully understood. The aim of this study is to detect the expression of HMGB1 and evaluate the role of HMGB1 in pancreatic cancer. Methods: The expression level of HMGB1 in pancreatic cancer cell line PANC-1 was detected by western blot analysis and reverse transcription PCR. Furthermore, primary tumors tissues of 35 patients with resected pancreatic cancer(T2-4 N0-2 M0-1) were stained immune histochemically using the polyclonal anti-HMGB1 antibody. The prognostic relevance of HMGB1 expression was evaluated by univariate Kaplan-Meier among 35 patients. Results: HMGB1 is over expressed in pancreatic cancer.HMGB1 overexpression was significantly associated with clinical stage (p<0.05). Univariate Cox regression showed that the survival time was significantly different between groups with high and low expression of HMGB1, indicating that high level of HMGB1correlated with a shorter survival time (P<0.05; HR, 2.53; 95%CI, 1.14-5.64). Conclusions: HMGB1 might promote pancreatic cancer progression and HMGB1 expression was an independent prognostic indicator for patients’ survival
